Prosecution Insights
Last updated: May 29, 2026

Changchun Genescience Pharmaceutical Co. Ltd.

3 pending office actions • 3 art units • 3 examiners • 0 of 3 (0%) have an AI response strategy ready • 2 patents granted in the last 365 days

Portfolio Summary

3
Total Pending OAs
2
Non-Final OAs
1
Final Rejections
0
Advisory / Quayle

Response Deadline Pressure

Based on the USPTO statutory response window for each pending office action. 3 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.

2
Overdue
0
Due this week
0
Due this month
1
Due in next 60 days
0
Due later

Deadline Fire Line

Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 3 of the docket's apps have a known mailing date.

-30dToday30d60d90d120d
Overdue (2)Due ≤ 60 days (1)

Case Difficulty Mix

Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.

0
Hard (0%)
3
Medium (100%)
0
Easy (0%)
0
Unknown (0%)

Rejection Statute Mix

BucketCases
§103 only3 (100%)

Industry Mix

How the docket's pending cases split across USPTO tech-center bands.

3
Life Sciences
100% of docket
0
Information Tech
0% of docket
0
Communications
0% of docket
0
Semiconductors
0% of docket
0
Mechanical / Eng
0% of docket
0
Business / Other
0% of docket

Time-on-OA Estimate

Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.

30 h
Manual time on pending OAs
6 h
Time saved (low, 20%)
10 h
Time saved (mid, 35%)
0.3 wks
FTE-weeks freed (mid)

Top Examiners on this docket

ExaminerApps on this docketAllow rateInterview lift
HAVLIN, ROBERT H 1 52.3% +27.2%
WELLS, LAUREN QUINLAN 1 45.6% +58.7%
SOROUSH, ALI 1 47.3% +30.0%

Interview Candidates (3)

Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 3 ordered by deadline are shown.

App #TitleExaminerDue in
18245293 APPLICATION OF ESTER GROUP-CONTAINING AROMATIC PROPIONAMIDE COMPOUNDS IN PREPARATION OF DRUGS FOR TREATING URINARY INCONTINENCE WELLS, LAUREN QUINLAN 145d overdue
18245055 USE OF ESTER GROUP-CONTAINING AROMATIC PROPIONAMIDE COMPOUND IN PREPARATION OF MEDICINE FOR TREATING DRY EYE SYNDROME SOROUSH, ALI 56d overdue
18553898 IMIDAZOLE-CONTAINING CONDENSED RING DERIVATIVE, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF IN MEDICINE HAVLIN, ROBERT H 60d

Top Art Units

Art UnitApps
1626 1
1622 1
1614 1

Pending Office Actions

App #TitleExaminerArt UnitStatutesStatusDue inAIFiled
18553898 IMIDAZOLE-CONTAINING CONDENSED RING DERIVATIVE, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF IN MEDICINE HAVLIN, ROBERT H 1626 §103 Non-Final OA 60d Pending Oct 04, 2023
18245293 APPLICATION OF ESTER GROUP-CONTAINING AROMATIC PROPIONAMIDE COMPOUNDS IN PREPARATION OF DRUGS FOR TREATING URINARY INCONTINENCE WELLS, LAUREN QUINLAN 1622 §103 Non-Final OA 145d overdue Pending Mar 14, 2023
18245055 USE OF ESTER GROUP-CONTAINING AROMATIC PROPIONAMIDE COMPOUND IN PREPARATION OF MEDICINE FOR TREATING DRY EYE SYNDROME SOROUSH, ALI 1614 §103 Final Rejection 56d overdue Pending Mar 13, 2023

Managing Changchun Genescience Pharmaceutical Co. Ltd.'s Patent Portfolio?

IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.

Start Free Trial

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month